HSP90AA1 and melanoma: In another report, resistance in melanoma patients was discovered following the use of the combination of the Hsp90 inhibitor XL888 with the BRAF inhibitor vemurafenib, but the use of dinaciclib as a CDK2 inhibitor abolished the resistance of patients to the combination [22].